Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Ping-Chih Hsu"'
Autor:
Chiao-Ping Chen, Tsai-Hsien Hung, Ping-Chih Hsu, Chun-Nan Yeh, Wen-Kuan Huang, Yi-Ru Pan, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu
Publikováno v:
Heliyon, Vol 10, Iss 22, Pp e40299- (2024)
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. Chemotherapy is crucial in NSCLC treatment, and targeting Wee1 kinase, a key regulator of the G2/M cell cycle checkpoint, may enhance the efficacy of
Externí odkaz:
https://doaj.org/article/f4213b2038d249e2b86209cfa475d6af
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 57, Iss , Pp 101039- (2024)
Non-small cell lung cancer (NSCLC) patients without targetable driver mutation have limited treatment options. In this study, we aimed to explore a new therapeutic strategy by using established nine patient-derived xenograft (PDX) and two-dimensional
Externí odkaz:
https://doaj.org/article/6530d2e7bdde4015866a68784ef2fa2b
Autor:
Li-Chung Chiu, Chung-Shu Lee, Ping-Chih Hsu, Hsin-Hsien Li, Tien-Ming Chan, Ching-Chung Hsiao, Scott Chih-Hsi Kuo, How-Wen Ko, Shu-Min Lin, Chun-Hua Wang, Horng-Chyuan Lin, Pao-Hsien Chu, Tzung-Hai Yen
Publikováno v:
Environmental Health, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Background Cadmium and nickel exposure can cause oxidative stress, induce inflammation, inhibit immune function, and therefore has significant impacts on the pathogenesis and severity of many diseases. Severe acute respiratory syndrome coron
Externí odkaz:
https://doaj.org/article/e05fa828c19e4c47b7eca4790db5da54
Autor:
Li‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang
Publikováno v:
Thoracic Cancer, Vol 15, Iss 7, Pp 529-537 (2024)
Abstract Background This study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutat
Externí odkaz:
https://doaj.org/article/f50013384c9245aabf156b8d88673574
Autor:
Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR subtype and generation of tyrosine kinase inhibitor (TKI) tre
Externí odkaz:
https://doaj.org/article/bce3fbab037c45f29c24a461f2f07a28
Autor:
Chen‐Te Wu, Ping‐Chih Hsu, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2548-2557 (2023)
Abstract Background This study aimed to comprehensively evaluate the efficacy and toxicity of afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and toxicity in patients with cancer. Methods The clinical featu
Externí odkaz:
https://doaj.org/article/fc07701970254cbbb9979c7ef0d94271
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
Autor:
Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR -mutant non-small-cell lung cancer. We
Externí odkaz:
https://doaj.org/article/cb59f58b72a54d5aa11a70e91bdabd7a
Autor:
Ping-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang, Li-Chung Chiu, Chiung-Hsin Chang, Ping-Chi Liu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Yu-Ching Lin, Cheng-Ta Yang, How-Wen Ko
Publikováno v:
Vaccines, Vol 12, Iss 5, p 474 (2024)
Real-world clinical experience of using anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (SCLC) patients has rarely been report
Externí odkaz:
https://doaj.org/article/fbd6cda30b6c4cde94dd95d9edb830f2
Autor:
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe clinical outcomes of sequential treatment of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs are unclear. Thus
Externí odkaz:
https://doaj.org/article/db4839ec0a994a6298da90412b223b41
Autor:
John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 4, Pp 348-356 (2023)
Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring the EGFR mutation. Patients experiencing intolerable adverse
Externí odkaz:
https://doaj.org/article/0d49cc0b61db45fda87814ded7764b7b